OSE Immunotherapeutics Share Price OTC Markets
Stocks
ORPHF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 74.32M 84.62M 69.12M 63.43M 119M 8.15B 121M 821M 321M 4.01B 318M 311M 13.85B | P/E 2026 * |
-2.43x | P/E 2027 * | -2.78x |
|---|---|---|---|---|---|
| Enterprise Value | 115M 131M 107M 98.24M 185M 12.62B 187M 1.27B 497M 6.21B 492M 481M 21.45B | EV / Sales 2026 * |
23.5x | EV / Sales 2027 * | 13x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | +190.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 01/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 19/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 19/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 30/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 13/06/2017 |
| Director/Board Member | - | 21/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +190.00% | +143.99% | - | - | 84.62M | |
| +1.07% | -3.49% | -3.35% | +11.75% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +647.65% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +60.81% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.31% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +43.00% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.44% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.10% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -34.51% | 12.7B | |
| Average | +19.20% | +0.83% | +54.56% | +107.74% | 27.25B | |
| Weighted average by Cap. | +0.54% | +0.91% | +74.42% | +138.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.58M 4.56M 4.18M 7.86M 537M 7.98M 54.11M 21.14M 264M 20.94M 20.49M 913M | 10.53M 11.99M 9.79M 8.99M 16.88M 1.15B 17.14M 116M 45.43M 568M 45.01M 44.04M 1.96B |
| Net income | -30.59M -34.82M -28.44M -26.1M -49.04M -3.35B -49.8M -338M -132M -1.65B -131M -128M -5.7B | -21.47M -24.44M -19.96M -18.32M -34.42M -2.35B -34.95M -237M -92.62M -1.16B -91.75M -89.78M -4B |
| Net Debt | 40.79M 46.44M 37.93M 34.81M 65.41M 4.47B 66.41M 450M 176M 2.2B 174M 171M 7.6B | 63.08M 71.83M 58.67M 53.83M 101M 6.92B 103M 697M 272M 3.4B 270M 264M 11.76B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
